The study analyzed that the proteasome inhibitor therapeutics pipeline comprises approximately 20 drug candidates in different stages of development. Protein degradation and synthesis in the body are regulated by proteasome activity of multimeric protease complex. The protein conjugated to multiple units of polypeptide proteasome ubiquitin are degraded by proteasome. The accumulation of ubiquitinated proteins can lead to apoptosis. The proteasome units include 20S core catalytic complex and 19S regulatory subunits at each end, forming 26S complex. Ubiquitin is 76 amino acids complex and covalently linked to proteins by an enzymatic reaction.
Insights on pipeline segments
According to the research findings, most of the drug candidates of the proteasome inhibitor therapeutics are being developed as the small molecules.
Access Report Summary with Detailed TOC on "Proteasome Inhibitors Therapeutics Pipeline, 2017 - Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments" at: https://www.psmarketresearch.com/market-analysis/proteasome-inhibitors-therapeutics
Advancements in Technologies Driving the Growth of Proteasome Inhibitor Therapeutics Candidates
Majority of companies in the pipeline have innovated various advanced technologies for developing drug candidates as proteasome inhibitors. For instance, Ensemble Therapeutics’, Corporation technology platform is an efficient and productive approach for developing synthetic macrocycles and other less conventional small molecules. While macrocycles are a class of compounds that have traditionally been obtained from natural sources, the company is synthesizing successfully the synthetic macrocycles possessing drug-like properties and features. Using this approach, the company has developed a pipeline of proprietary and partnered programs that focus on both extracellular proteins (e.g. IL-17) and challenging intracellular targets (e.g. IAPs, IDO and USP9x).
Various Collaborations for Proteasome Inhibitor Therapeutics Development
Viteava Pharmaceuticals Inc. (Viteava) announced the execution of a sponsored research agreement with McGill University relating to novel analogs and derivatives of the green tea flavonoid, (-) epigallocatechin-3-gallate (EGCG).
Some of the key players developing drugs as proteasome inhibitors include Triphase Accelerator Corporation, Cantex Pharmaceuticals, Inc., Accuitis, Inc. and others.
Proteasome Inhibitor Therapeutics Pipeline Analysis